Victoria P. Werth, MD, discusses how litifilimab’s 52-week AMETHYST findings inform treatment expectations and timely reassessment of persistent cutaneous lupus symptoms.
|Articles|April 15, 2020
Pharmacy Heroes: Kentucky Pharmacists Fit Test N95 Masks, Disseminate Information to Team Members
Today, we’re thanking Jessica Tackett, PharmD, BCPS, and Brittany Bissell, PharmD, PhD, BCCCP, both of whom work in the University of Kentucky (UK) HealthCare system.
Advertisement
Tackett (left) and Bissell (right)
Today, we’re thanking Jessica Tackett, PharmD, BCPS, and Brittany Bissell, PharmD, PhD, BCCCP, both of whom work in the University of Kentucky (UK) HealthCare system.
Tackett is a clinical pharmacist who has been fit-testing N95 masks for the many pharmacists who work at UK HealthCare Good Samaritan Hospital, in addition to taking care of the daily work of pharmacists and caring for her 2 kids at home.
Bissell is a critical care pharmacist who has been gathering evidence-based resources and distributing the information to the group, ensuring that everyone is up-to-date on the latest news regarding the coronavirus disease 2019 (COVID-19) pandemic.
Pharmacy Times wants to celebrate the amazing pharmacy staff members who are on the front lines every day. Nominate someone in your pharmacy by emailing
Advertisement
Related to this article
In an interview with Pharmacy Times, Victoria P. Werth, MD, professor of dermatology at the University of Pennsylvania and chief of dermatology at the Philadelphia VA Medical Center, discusses why meaningful improvement extends beyond skin clearance and how response timing affects patients with difficult-to-control disease.
As psychedelic therapies advance through clinical development, pharmacists should prepare for potential roles in their safe, evidence-based integration into patient care.
In an interview with Pharmacy Times, Ali A. Habib, MD, clinical professor of neurology at the University of California, Irvine, discusses what the hospitalization findings mean for patients and why they should be viewed as supportive evidence
The FDA approval of pritelivir offers an oral treatment for refractory HSV lesions in immunocompromised adults, with drug interactions creating an important role for pharmacists.
Weltruza, the first subcutaneous long-acting injectable (LAI) formulation of olanzapine, requires no loading doses, oral supplementation, or postinjection monitoring.
The first AHA endocarditis update in 11 years expands outpatient options, with a bigger role for pharmacists.
Investigational inhaled stem cells for COPD raise questions about lasting clinical benefit and the pharmacy controls needed to deliver a living-cell product through a nebulizer.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Pneumonic Plague: What Pharmacists Need to Know About Treatment
2
Could Cemdisiran Keep Patients With Myasthenia Gravis Out of the Hospital?
3
FDA Approves Pritelivir for Refractory HSV Lesions in Immunocompromised Adults
4
FDA Approves First Once-Monthly Subcutaneous Olanzapine LAI for Adults With Schizophrenia
5